Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease

NCT00348140 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00348140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00348140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54 Week, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Acetylcholinesterase Inhibitors on Cognition and Overall Clinical Response in APOE4-stratified Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
July 12, 2006
Completion date
March 20, 2009
Enrollment
1,468 (actual)
Sites
194

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease